A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer

Inclusion Criteria: * Surgical resection of histologically confirmed Stage IIA to IIIA NSCLC with negative margins, ,within 10 weeks after the operation * Documented ALK-positive disease according to FISH , Ventana IHC ,RT-PCR or NGS * Eastern Cooperative Group (ECOG) Performance Status score of 0 or 1 * At least 3-months life expectancy * Adequate organ function * Any major surgery should be completed at least 4 weeks before the first study drug treatment. Minor surgery/procedures must be completed at least 2 weeks before taking medication. * Willingness and ability to comply with the trial and follow-up procedures * Written informed consents are required to indicate that the patients are aware of the investigational nature of the study Exclusion Criteria: * More than 10 weeks before surgery Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ * Use of other investigational drug within 4 weeks prior to the first dose of Ensartinib * Prior stem cell or organ transplant * severe cardiovascular disease * Presence of active gastrointestinal (GI) disease or other conditions that will interfere significantly with the absorption, distribution, metabolism, or excretion of Ensartinib * Active hepatitis B, hepatitis C virus antibody positive, HIV virus antibody, Treponema pallidum antibody positive * History of interstitial lung disease, drug-induced interstitial lung disease, history …